MANGALAM — Mangalam Drugs and Organics Share Price
0.000.00%
Last trade - 00:00- IN₹1.67bn
- IN₹2.60bn
- IN₹3.69bn
- 71
- 58
- 61
- 73
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.24 | ||
| Price to Tang. Book | 1.57 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.46 | ||
| EV to EBITDA | 14.99 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 1.62% | ||
| Return on Equity | -6.31% | ||
| Operating Margin | 0.74% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 2,823.54 | 3,801.41 | 4,510.68 | 3,722.53 | 3,685.95 | n/a | n/a | 10.12% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | +237.77 | -29.78 | -93.53 | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Mangalam Drugs and Organics Limited is an India-based manufacturer of active pharmaceutical ingredients (APIs) and intermediates. Under the Company's Fight Malaria Program, it supplies anti-malaria APIs worldwide. Its products include API, intermediates and specialty chemicals. Its API products include acyclovir, amodiaquine, artemether, artesunate, atazanavir sulfate, bisoprolol fumarate, chloroquine phosphate, furosemide and dolutegravir sodium. The Company's intermediates products include 4,6-Dichloro-5-Methoxy Pyrimidine; 4,7- dichloroquinoline; ortho phenoxy methane sulfonanilide; tenofovir alafenamide base, and tenofovir disoproxil base. Its specialty chemicals products include L (+)-menthol; 2,3-dihydrophthalazine-1,4-dione or phthalazine-1,4-dione, and 4-cynoethyl-2-methyl phenol. Its pipeline APIs (under development) include Ganaplacide (IH), Tafenoquine Succinate (IH) and Pretomanid (IH). Its pipeline APIs (developed at research and development) is Bictegravir Na (IH).
Directors
- Govardhan Dhoot CHM (60)
- Ajay Samant CFO
- Jayant Barde CCO (27)
- Brijmohan Dhoot EDR
- Rukmesh Dhandhania NID (37)
- Nidhi Mundada NID
- Praveen Saxena NID (65)
- Last Annual
- March 31st, 2024
- Last Interim
- March 31st, 2024
- Incorporated
- April 18th, 1972
- Public Since
- May 26th, 2005
- No. of Employees
- 523
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 15,828,248
- Address
- 3Rd Floor, MUMBAI, 400001
- Web
- https://www.mangalamdrugs.com/
- Phone
- +91 2222616200
- Auditors
- V.S. Somani & Co.
Upcoming Events for MANGALAM
Mangalam Drugs and Organics Ltd Annual Shareholders Meeting
Q2 2024 Mangalam Drugs and Organics Ltd Earnings Release
Q4 2024 Mangalam Drugs and Organics Ltd Earnings Release
Similar to MANGALAM
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
What is the Mangalam Drugs and Organics share price?
As of Today at 15:57 UTC, shares in Mangalam Drugs and Organics are trading at IN₹106.09. This share price information is delayed by 15 minutes.
How has the Mangalam Drugs and Organics share price performed this year?
Shares in Mangalam Drugs and Organics last closed at IN₹106.09 and the price had moved by -4.08% over the past 365 days. In terms of relative price strength the Mangalam Drugs and Organics share price has underperformed the S&P BSE 100 Index by -26.71% over the past year.
What are the analyst and broker recommendations for Mangalam Drugs and Organics?
The overall consensus recommendation for Mangalam Drugs and Organics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Mangalam Drugs and Organics dividend yield?
Mangalam Drugs and Organics does not currently pay a dividend.
Does Mangalam Drugs and Organics pay a dividend?
Mangalam Drugs and Organics does not currently pay a dividend.
When does Mangalam Drugs and Organics next pay dividends?
Mangalam Drugs and Organics does not currently pay a dividend.
How do I buy Mangalam Drugs and Organics shares?
To buy shares in Mangalam Drugs and Organics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Mangalam Drugs and Organics?
As of the previous close price of IN₹106.09, shares in Mangalam Drugs and Organics had a market capitalisation of IN₹1.68bn.
Where are Mangalam Drugs and Organics shares listed?
Here are the trading details for Mangalam Drugs and Organics:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: MANGALAM
What kind of share is Mangalam Drugs and Organics?
Based on an overall assessment of its quality, value and momentum Mangalam Drugs and Organics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Mangalam Drugs and Organics share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Mangalam Drugs and Organics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Mangalam Drugs and Organics. Over the past six months, its share price has underperformed the S&P BSE 100 Index by -3.63%.
As of the last closing price of IN₹106.09, shares in Mangalam Drugs and Organics were trading +2.4% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Mangalam Drugs and Organics PE Ratio?
The Mangalam Drugs and Organics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹106.09.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Mangalam Drugs and Organics?
Mangalam Drugs and Organics' management team is headed by:
- Govardhan Dhoot - CHM
- Ajay Samant - CFO
- Jayant Barde - CCO
- Brijmohan Dhoot - EDR
- Rukmesh Dhandhania - NID
- Nidhi Mundada - NID
- Praveen Saxena - NID